Gurvinder Singh Rekhi, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gurvinder Singh Rekhi, PhD


Gurvinder Singh Rekhi, PhD
Director, R&D,
Elan Drug Delivery, Inc.

Gurvinder Singh Rekhi, PhD, is currently director of research and development at Élan Drug Inc. in Gainesville, Georgia, managing the activities of the formulation and analytical development, scale-up/transfer, and validation of controlled release dosage forms. He is responsible for regulatory submissions for three NDAs, and he represents the company in contract negotiations, scientific/technical presentations, and intellectual property.

Rekhi is currently an adjunct assistant professor of pharmaceutics at the University of Maryland, School of Pharmacy, as well as an associate professor at the Massachusetts College of Pharmacy. Rekhi also serves as an advisory board member for the Center for Drug Delivery Research at Mercer University, Southern School of Pharmacy.

Rekhi is a member of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), APhA, CRS, and Rho Chi Pharmaceutical Honor Society. He serves as an editorial board member of Pharmaceutical Technology and ad hoc reviewer for several pharmaceutical journals. He has served as a committee member on one MS, five PhD dissertations and directed two post-doctoral fellows. He has published and presented scientific papers in the US and at international conferences, and he holds numerous patents from the US Patent Office and several EU countries. He has co-authored chapters in the NABPLEX Pharmacy Review Book and the Handbook of Pharmaceutical Granulation Technology.

Rekhi received his B. Pharm. (1983) from Bombay College of Pharmacy, India. He obtained his MS (1986), BS (1989), and PhD (1991) degrees in Pharmaceutics and Industrial Pharmacy from Massachusetts College of Pharmacy. Rekhi is a registered pharmacist in the states of Connecticut, Maryland, and Georgia.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here